Last reviewed · How we verify

NCT02848508: METsuiviIRC

Metformin in Moderate and Severe Renal Failure (CKD 3-4): A Follow-up Study

Withdrawn Phase 2 Last updated 15 July 2020
What this trial tests

Phase 2 trial testing Metformin in Renal Insufficiency, Chronic. Withdrawn.

Timeline
16 March 2016
Primary endpoint
7 June 2017
7 June 2017

Quick facts

Lead sponsorCentre Hospitalier Universitaire, Amiens
PhasePhase 2
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Start date16 March 2016
Primary completion7 June 2017
Estimated completion7 June 2017
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire, Amiens

Who can join

Adults 18 to 80, any sex, with Renal Insufficiency, Chronic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To validate on the mid-term in moderate and severe renal failure (CKD 3-4) a nomogram to adapt a fixed metformin daily posology according to renal function on the basis of the first short-term study made by the investigators.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

Other recruiting trials for Renal Insufficiency, Chronic

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire, Amiens trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02848508.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing